Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus BRETHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus BRETHINE.
BRETHAIRE vs BRETHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist